6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma (VA-21-00000590)

Pre-Solicitation Posted

This opportunity was awarded. See the award notice from , or the latest solicitation from .

Solicitation number
36E79720R0068
Agency
Responses due
Not on record
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

This notice announces the Department of Veterans Affairs' intent to issue solicitation number 36E79720R0068 to procure subcutaneous anti-interleukin monoclonal antibodies for asthma for the VA, DoD, BOP, and IHS. The VA seeks to award a one-year contract with four one-year option periods to supply mepolizumab, dupilumab, and benralizumab in various dosages and package configurations. Interested parties should monitor FedBizOpps for the solicitation release on September 16, 2020, with responses due by September 30, 2020. The VA will evaluate offers and award to the responsible offeror able to provide an uninterrupted supply.

There is no set-aside designated for this procurement. The NAICS code is 325412. The estimated annual patient populations are 3,880 for VA, 552 for DoD, 18 for BOP, and 200 for IHS, totaling approximately 4,650 patients. Offerors must specify the exact product name and National Drug Code number for the antibodies to be provided. Questions are due to Christopher Carthron by email. The contract will distribute pharmaceuticals through the VA and DoD Prime Vendor programs for an estimated 13 packs of 26 syringes of dupilumab and 6.5 doses each of benralizumab.

Notice text

PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79720R0068 for an unrestrictive procurement for Anti-Interleukin Monoclonal Antibodies for Asthma, for the Department of Veterans Affairs (VA), Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the antibodies will be supplied and have a unique NDC number. Solicitation #36E79720R0068 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about September 16, 2020, with a tentative closing date of September 30, 2020. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.fedbizopps.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Chris Carthron. Questions can be e-mailed to: Christopher.Carthron@va.gov.

The estimated annual requirements are as follows:

ITEM

Packages

DESCRIPTION

Dosing

Doses/Year

1a

1

MEPOLIZUMAB 100MG/VIL INJ

100mg Q 4 weeks

13

1b

1

MEPOLIZUMAB 100MG/ML,AUTO INJCT

100mg Q 4 weeks

13

1c

1

MEPOLIZUMAB 100MG/ML,SYRINGE

100mg Q 4 weeks

13

OR

OR

OR

OR

OR

2a

1

DUPILUMAB 150MG/ML INJ,SYR,2ML 2 SYRINGES PER PACK

400-600mg loading dose then 200mg or 300mg every other week

13 packs of 2, or 26 syringes

2b

1

DUPILUMAB 200MG/1.14ML INJ,SYR 2 SYRINGE PER PCK

400-600mg loading dose then 200mg or 300mg every other week

26

OR

OR

OR

OR

OR

3a

1

BENRALIZUMAB 30MG/ML INJ,SYR,1ML

30mg Q 4 weeks x 3 doses then Q 8 weeks

6.5

3b

1

BENRALIZUMAB 30MG/ML INJ,PEN,1ML

30mg Q 4 weeks x 3 doses then Q 8 weeks

6.5

Agency

Number of Patients For Respiratory Use Only

VA

3,880

DoD

552

BOP

18

IHS

200

Total Estimated Patients Annually 4,650

Files

File Type Posted
36E79720R0068_1.docx DOCX document

Notice history

Notice Type Posted
6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma/Benralizumab Award Award Notice
6505--Subcutaneous Anti-Interleukin Monoclonal Antibodies for Asthma (VA-21-00000590) Latest solicitation Solicitation
This notice Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Epinephrine Injector NAICS 325412 Medical Supply Chain No set-aside
6505--FY27 Lenalidomide BPA Department of Veterans Affairs Participating VA Medical Centers · NAICS 325412 Veterans Integrated Service Network 22 No set-aside
6550--Cepheid GeneXpert Testing Supplies Beckley Vamc Clarksburg Vamc Vamhcs Washington Vamc · NAICS 325413 Veterans Integrated Service Network 5 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors